Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2
South Korea’s five major legacy pharmaceutical companies largely extended their revenue growth in the second quarter, but their bottom lines diverged...
Search results for "earnings"
Early Retirement and Youth Unemployment Leave Middle-Aged Mothers Bearing the Domestic Burden
Imagine a household where both the husband and an adult child remain at home all day—the husband forced into early retirement and the son still...
Celltrion Chairman Seo Jung-jin Forgoes Summer Vacation for Global Business Tour Targeting Record Second Half
Celltrion Group Chairman Seo Jung-jin will forgo his summer vacation this August to embark on an intensive overseas...
South Korea Overhauls Pharma and Biotech Disclosure Rules Following Samchundang Controversy
South Korean financial authorities are overhauling disclosure regulations across the pharmaceutical and biotechnology...
Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%
Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major...
Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms
Samsung Biologics reported second-quarter revenue in the 1.3 trillion won range this year, a 30% increase from the same...
Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs
With wage and collective bargaining talks between Samsung Biologics and its union still unresolved, analysts expect...
Eli Lilly to Acquire GC Biopharma’s Curevo Vaccine in Blockbuster $1.5 Billion Deal
GC Biopharma’s U.S. affiliate, Curevo Vaccine, is set to be acquired by global pharmaceutical giant Eli Lilly in a deal...
Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?
“It doesn’t end with lazertinib. Keep an eye out for the next candidate in line.” Oscotec is aggressively channeling...
Sam Chun Dang Pharm Secures Exclusive U.S. Licensing Deal for Oral Obesity and Diabetes Treatment
Sam Chun Dang Pharm has entered into a significant license-out agreement with an undisclosed U. S.